Fisher and Paykel Healthcare's stock has risen 52% year-to-date, despite facing pressure due to a high price-to-earnings (P/E) ratio of 103, which could drop to 60 even with a 40% profit increase. Historically, investors preferred buying at a P/E of 20 to 25, suggesting a hold rating at current valuations. The company has maintained growth post-pandemic through effective cost management, despite shifting market expectations.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.